Rational approach to Xtandi resistance

A group led by researchers at the Memorial Sloan-Kettering Cancer Center has identified a mutation in the androgen receptor that could drive resistance to second-generation antiandrogen drugs such as

Medivation Inc.'s Xtandi enzalutamide. The team's subsequent rational drug design studies yielded a series of molecules that could overcome the resistance mechanism.¹...